Skip to main content

Table 1 Details of study populations

From: Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis

Study name

Study Type (Cohort name)

 

Study period

Age (Mean) of participants

Sex (Male (%))

Primary outcome(Disease)

Location

Study size(N)

 

Race/ethnicity (%)

Average follow up(years)

Total Events

Method for eGFR (< 60 ml/min/1.73m2)

Atta, 2006 [8]

Cohort

 

1995-2004

42.8

58

HIVAN

MD, USA

263

 

96(B)

8.0

36

MDRD

Buskin, 2009 [9]

Cohort

 

1996-2003

36.5

 

HIVAN

USA

59705

 

6.2(W)

3.5

5042

MDRD

          

11.5(B)

   
          

7.3(H/L)

   
          

6.5(A/PI)

   
          

9.7(NA/AN)

   
          

4.7(O)

   

Campbell, 2009 [10]

cross-sectional

 

1998-2005

 

--

CKD

BT, UK

3439

 

NR

--

81

MDRD

Crane, 2007 [4]

Cohort(UWHIV)

 

2001-2006

41

83

Kidney dysfunction

WA, USA

445

 

61(W)

--

51

CG

          

23(AA)

   
          

16(O)

   

Crum-Cianflone, 2010 [11]

cross-sectional

 

2004-2005

41

92

Kidney dysfunction

CA, MD, USA

717

 

48.7 (C)

--

22

MDRD

          

37.9(AA)

   
          

13.4 (O)

   

Deti, 2010 [7]

Cohort(ANRS CO3)

 

2004-2008

43

75

CRF

France

2613

 

NR

3.4

 

MDRD

Franceschini, 2006 [12]

Cohort

 

2000-2002

40

69

ARF

NC, USA

705

 

66(AA)

3.0

 

serum creatinine

Franey, 2009 [13]

Cohort

 

2004-2007

36

31.2

RI

South Africa

2189

 

NR

--

287

MDRD

Ganesan, 2010 [14]

Cohort (P)

 

1986-2008

29

92

CKD

USA

4044

 

45(AA)

6.5

90

MDRD

          

44(EA)

   

Heffelfinger, 2006 [15]

Cohort

 

2000-2003

--

--

RI

USA

11362

 

NR

 

724

serum creatinine

Horberg, 2010 [3]

Cohort(KP)

 

2002-2005

43

86.1

Tubular dysfunction

CA, ML, VA, USA

1647

 

24.5(B)

2.0

 

MDRD

Ibrahim, 2010 [2]

Cohort(KCH)

 

1999-2008

37

62

ARF

SL, UK

2556

 

55.4(B)

--

184

MDRD

          

44.6(W/O)

   

Jacobson, 2007 [16]

Cohort(MACS)

    

Proteinuria

USA

1203

 

(B)

 

120

 

Jones, 2004 [17]

Cohort(CWS)

    

Renal dysfunction

UK

4183

 

NR

 

1175

serum creatinine > 120

Krawczyk, 2004 [18]

Cohort(HOPS)

 

1992-2002

43

82.5

CRF

GA, USA

6361

 

43.8(W/NH)

 

108

--

          

5.0(H)

   
          

48.8(B)

   
          

2.5(O)

   

Longenecker, 2009 [19]

Cohort(P)

 

2004-2007

41

68

CKD

CA, USA

554

 

42(AA)

5.0

 

CKD-EPI

          

48(W)

   
          

10(O)

   

Lucas, 2007 [20]

Cohort(ALIVE/JHHC)

 

1988-2005

37

68

ESRD/RRT

MD, USA

6255

 

(AA)

5.7

221

MDRD

Mocroft, 2010 [21]

Cohort(EuroSIDA)

 

2004-2008

43

75.1

CKD

Europe, Israel, Argentina

  

85.5(W)

3.7

225

CG

Reisler, 2005 [22]

Cohort(MACS)

 

2003-2004

--

--

CKD

USA

1470

 

NR

 

53

MDRD

Roe, 2008 [23]

Cohort (R)

 

1998-2005

35.9

64

ARF

SEL, UK

2274

 

64(B)

8.0

130

MDRD

          

36(NB)

   

Szczech, 2002 [24]

Cohort(WIHS)

  

40

--

  

2059

 

71.4(B)

 

671.0

double serum creatinine

          

16.7(W)

   
          

11.9(H)

   
          

0(O)

   

Vanig, 2008 [25]

Cohort (R)

 

2006-2007

--

94

CKD

USA

375

 

NR

  

MDRD

Wei, 2003 [26]

Cohort(P)

  

37.6

93.2

HIVAN

NY, USA

44

 

(AA)

 

44

 
 

Study group1

 

Study group2

    
 

Study description

Sample size (n1)

Event1

Incidence(per 1000py)

 

Study description

 

Sample size (n2)

Event2

Incidence(per 1000py)

HR/RR/OR

95% CI

Study name

            

Atta, 2006 [8]

ART

--

26

--

 

Treatment naïve

 

--

10

--

0.3

0.09, 0.98

Buskin, 2009 [9]

Indinavir

    

Treatment naïve

    

1.15

1.02, 1.29

 

Ritonavir

    

Treatment naïve

    

0.87

0.77, 0.98

 

HAART

    

Treatment naïve

    

0.3

0.27, 0.34

Campbell, 2009 [10]

Age > = 50 years(Indinavir)

 

--

--

 

Age < 50 years

  

--

--

4.92

1.31, 18.4

 

Indinavir/per year

         

1.29

1.00, 1.65

 

Age > = 50 years(Tenofovir)

    

Age < 50 years

    

5.42

1.71, 16.8

Crane, 2007 [4]

Age (30-40) years

    

Age < 30 years

    

0.9

0.2, 3.2

 

Age (40-50) years

    

Age < 30 years

    

2.1

0.6, 7.6

 

Age > 50 years

    

Age < 30 years

    

4.4

1.1, 17.2

 

(NRTI)Didanosine

    

(NRTI)lamivudine/emtricitabine

    

3.1

1.40, 6.80

 

PI(Amprenavir/fos-amprenavir)

    

NNRTI (efavirenz)

    

3.6

1.00, 12.5

Crum-Cianflone, 2010 [11]

Age/10 year increase

         

1.99

1.22, 3.24

 

Tenofovir/per year

         

1.54

1.10, 2.15

Deti, 2010 [7]

Age/10 year increase

         

2.2

1.8, 2.6

 

CD4 < 200 cells/mm3

    

CD4 > 500 cells/mm3

    

4.04

2.3, 7.1

 

Tenofovir/per year

         

1.4

1.1, 1.8

Franceschini, 2006 [12]

CD4 < 200 cells/mm3

    

CD4 > = 200 cells/mm3

    

4.7

2.5, 8.8

Franey, 2009 [13]

CD4 < 100 cells/mm3

    

CD4 > 100 cells/mm3

    

1.4

1.07, 1.82

 

Age > 40 years

    

Age < 40 years

    

4.65

3.54, 6.10

Ganesan, 2010 [14]

Age > = 35 years

    

Age < 35 years

    

2.6

1.7, 4.0

 

CD4 < = 200 cells/mm3

    

CD4 > = 500 cells/mm3

    

6.8

3.0, 15.5

 

CD4(201-349) cells/mm3

    

CD4 > = 500 cells/mm4

    

4.3

2.3, 8.1

 

CD4(350-499) cells/mm3

    

CD4 > = 500 cells/mm5

    

2.4

1.3, 4.6

Heffelfinger, 2006 [15]

Tenofovir

    

Treatment naïve

    

1.5

1.1, 1.9

Horberg, 2010 [3]

Tenofovir

964

   

Non-Tenofovir

 

683

  

5.23

2.08, 13.1

Ibrahim, 2010 [2]

Age/10 year increase

         

1.04

0.87, 1.24

 

Indinavir

    

Treatment naïve

    

1.81

0.53, 6.76

 

Tenofovir

    

Treatment naïve

    

1.06

0.46, 2.43

 

Atazanavir

    

Treatment naïve

    

1.05

0.20, 5.49

 

CART

    

Treatment naïve

    

1.11

0.54, 2.30

 

CD4(201-350) cells/mm3

    

CD4 > 350 cells/mm3

    

1.56

0.97, 2.48

 

CD4(101-200) cells/mm3

    

CD4 > 350 cells/mm3

    

2.08

1.11, 3.91

 

CD4(51-100) cells/mm3

    

CD4 > 350 cells/mm3

    

6.38

3.18, 12.78

 

CD4(0-50) cells/mm3

    

CD4 > 350 cells/mm3

    

10.29

5.11, 20.98

Jacobson, 2007 [16]

HIV

94

   

Non-HIV

 

26

  

5.1

2.9, 8.9

Jones, 2004 [17]

Tenofovir

1058

84

  

Treatment naïve

    

0.22

0.07, 0.69

Krawczyk, 2004 [18]

CD4 < 200 cells/mm3

    

200-349 cells/mm3

    

4.3

2.1, 8.7

 

HAART

    

Treatment naïve

    

0.5

0.3, 1.0

Longenecker, 2009 [19]

HIV

337

26

  

Non-HIV

 

230

2

 

6.5

1.5, 28.7

 

Age/10 year increase

         

1.34

1.02, 1.77

Lucas, 2007 [20]

AIDS

1902

125

12.7

 

No AIDS

 

2607

51

4.7

2.7

1.9, 4.0

 

Age(30-49.9)

    

Age < 30 years

    

1.5

0.7, 3.3

 

Age > = 50 years

    

Age < 30 years

    

2

0.8, 4.7

 

AIDS

1902

  

Non-HIV

 

1751

  

5.1

3.5, 7.6

 

HIV

2607

   

Non-HIV

 

1751

  

2.3

1.5, 3.5

Mocroft, 2010 [21]

AIDS

    

No AIDS

    

2.22

1.14, 4.32

 

Age/10 year increase

         

1.54

1.31, 1.80

 

Tenofovir/per year

         

1.16

1.06, 1.25

 

Indinavir/per year

         

1.12

1.06, 1.18

 

Atazanavir/per year

         

1.21

1.09, 1.34

 

Lopinavir/r per year

         

1.08

1.01, 1.16

Reisler, 2005 [22]

HIV

 

32

  

Non-HIV

  

21

 

2.5

1.4, 4.5

 

Tenofovir

    

Non-Tenofovir

    

2

0.8, 4.9

Roe, 2008 [23]

CD4 < 100 cells/mm3

    

CD4 > 200 cells/mm3

    

6.75

2.5, 18.3

 

CD4(100-199) cells/mm3

    

CD4 > 200 cells/mm3

    

3.02

0.99, 9.13

 

AIDS

    

No AIDS

    

6.7

3.4, 13.3

Szczech, 2002 [24]

CD4 < = 200 cells/mm3

    

CD4 > 200 cells/mm3

    

3.57

1.72, 7.14

Vanig, 2008 [25]

Tenofovir

253

   

Non-Tenofovir

 

122

  

1.83

1.11, 3.02

 

PI

    

Non-PI

    

1.27

0.84, 1.91

Wei, 2003 [26]

ART

    

Treatment naïve

    

1.51

0.37, 6.20

 

CD4 < = 100 s cell/mm3

    

CD4 > = 100 cells/mm3

    

2.73

0.82, 9.14

  1. A, Asian; AA, African-American; B, Black; EA, European American; H, Hispanic; NH, Non-Hispanic; L, Latino; NB, Non-b lack; PI, Pacific Islander; NA, Native American; AN, Alaska Native; W, White; O, Others; MD, Maryland; NC, North Carolina; WA, Washington; GA, Georgia; SL South London; SEL, Southeast London; BT, Brighton; NR, Not Reported; NA, Not Applicable; Sr, Serum; R, Retrospective; P, Prospective; WIHS, Women's Interagency HIV Study; UWHIV, University of Washington HIV; ALIVE, AIDS Link to the Intravenous Experience; JHHC, Johns Hopkins HIV Cohort; KP, Kaiser Permanente; MACS, Multicentre AIDS Cohort Study; CWS, Chelsea and Westminster; HOPS, HIV Outpatient Study; KCH, Kings College Hospital; ANRS CO3, National agency for AIDS research Aquitaine Cohort; MDRD, Modification of Diet in Renal Disease-an equation to estimate GFR that incorporates serum creatinine, age, sex and race; CG, Cockcroft-Gault equation to estimate GFR that incorporates serum creatinine, age, sex and weight; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration-an equation that take into account serum creatinine, age, sex and race.